Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Nanjing Vazyme Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	475.66	434.25	1,967	1,545	1,478	221.6
Trading Asset Securities	2,430	2,222	1,514	1,719	1,976	795.65
Cash & Short-Term Investments	2,906	2,656	3,481	3,264	3,454	1,017
Cash Growth	-4.54%	-23.69%	6.65%	-5.49%	239.50%	984.22%
Accounts Receivable	491.53	483.61	351.93	839.62	322.32	226.24
Other Receivables	10.52	20.81	4.07	7.72	4.67	4.57
Receivables	502.05	504.42	356.01	847.35	326.99	230.81
Inventory	374.28	362.18	346.25	364.2	242.19	132.37
Prepaid Expenses	-	0.05	-	-	-	-
Other Current Assets	80.6	48.58	47.12	89.71	28.1	15.27
Total Current Assets	3,863	3,571	4,230	4,565	4,051	1,396
Property, Plant & Equipment	672.63	726.07	767.3	679.48	308.98	128.5
Long-Term Investments	64.72	54.83	47.3	22.31	18.48	-
Goodwill	130.49	130.49	130.49	130.49	-	-
Other Intangible Assets	88.31	95.19	101.24	49.7	16.65	7.42
Long-Term Accounts Receivable	-	0.15	-	-	-	-
Long-Term Deferred Tax Assets	154.51	146.04	106.51	67.12	24.87	9.09
Long-Term Deferred Charges	251.69	278.91	280.54	318.31	145	62.72
Other Long-Term Assets	41	45.51	82.53	172.69	42.25	8.22
Total Assets	5,266	5,049	5,746	6,005	4,607	1,612
Accounts Payable	78.56	90.4	146.82	318.78	118.76	58.58
Accrued Expenses	59.66	129.74	112.52	258.07	104.7	54.62
Short-Term Debt	914.57	551.32	1,134	272.21	-	1.15
Current Portion of Leases	25.59	57.03	46.16	58.25	31.25	-
Current Income Taxes Payable	8.23	0.6	0.03	0.54	20.02	31.57
Current Unearned Revenue	51.84	54.87	55.92	214.55	95.03	85.42
Other Current Liabilities	21.13	19.36	24.09	31.67	17.5	7.89
Total Current Liabilities	1,160	903.33	1,520	1,154	387.26	239.23
Long-Term Leases	149.27	143.36	106.89	127.68	59.93	-
Long-Term Unearned Revenue	47.99	48.38	21.38	19.25	16.24	15.36
Long-Term Deferred Tax Liabilities	0.73	1.26	1.51	11.19	0.87	0.1
Other Long-Term Liabilities	7.88	8.72	67.6	80.92	15.52	24.59
Total Liabilities	1,365	1,105	1,717	1,393	479.83	279.28
Common Stock	397.73	402.13	400.01	400.01	400.01	360
Additional Paid-In Capital	2,365	2,512	2,442	2,429	2,422	345.3
Retained Earnings	1,141	1,139	1,209	1,780	1,305	627.06
Treasury Stock	-	-104.4	-20.01	-	-	-
Comprehensive Income & Other	-2.36	-3.97	-1.72	-	-	-
Total Common Equity	3,901	3,945	4,029	4,609	4,127	1,332
Minority Interest	-0.35	-1.63	-0.11	3.2	-	-
Shareholders' Equity	3,901	3,944	4,029	4,612	4,127	1,332
Total Liabilities & Equity	5,266	5,049	5,746	6,005	4,607	1,612
Total Debt	1,089	751.71	1,287	458.14	91.18	1.15
Net Cash (Debt)	1,817	1,905	2,194	2,806	3,362	1,016
Net Cash Growth	-7.41%	-13.19%	-21.81%	-16.56%	230.91%	1647.85%
Net Cash Per Share	5.56	5.26	5.57	7.03	9.27	2.86
Filing Date Shares Outstanding	397.73	397.82	397	400.01	400.01	360
Total Common Shares Outstanding	397.73	397.82	397	400.01	400.01	360
Working Capital	2,703	2,668	2,711	3,411	3,664	1,156
Book Value Per Share	9.81	9.92	10.15	11.52	10.32	3.70
Tangible Book Value	3,682	3,720	3,798	4,429	4,111	1,325
Tangible Book Value Per Share	9.26	9.35	9.57	11.07	10.28	3.68
Machinery	-	712.88	656.11	513.97	250.31	119.03
Construction In Progress	-	69.42	127.48	69.44	-	36.81

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.